Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy

NCT03071133 · clinicaltrials.gov ↗
COMPLETED
Status
344
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

Bristol-Myers Squibb